Regeneron Pharmaceuticals (REGN) 10-K Summaries & Annual Filing History
Review Regeneron Pharmaceuticals, Inc. (REGN) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Regeneron Pharmaceuticals reported a modest increase in revenue for the most recent fiscal year. The company continues to invest in expanding its manufacturing and research facilities.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$14.3B
Revenue reported for the fiscal year.
Operating income
$3.6B
Income from operations reported for the year.
Net income
$4.5B
Net income reported for the year.
Operating cash flow
$5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $12.2B | -24.3% |
| Dec 31, 2023 | $13.1B | +7.8% |
| Dec 31, 2024 | $14.2B | +8.3% |
| Dec 31, 2025 | $14.3B | +1.0% |
Business overview
The company is a biopharmaceutical firm engaged in the research, development, and manufacturing of medicines. It operates research and manufacturing facilities, including a headquarters in Tarrytown, New York, and is developing additional sites for production support and capacity expansion.
Financial performance
Revenue grew slightly compared to the prior year. Operating income and net income were substantial, and cash generated from operations was strong.
Material risks
The filing references a risk factors section but does not provide specific details within the supplied context. The company faces typical industry risks related to regulatory approvals and commercial production readiness.
Liquidity and capital
The company is investing in expanding its manufacturing capacity, including the development of a parcel adjacent to its headquarters and a newly acquired facility in Saratoga Springs. It also has a lease financing facility for its corporate headquarters.
What to watch
Monitor the approval status of the Rensselaer fill/finish facility, which is undergoing process validation and has not yet been approved for commercial production.